Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl induced leukemia
暂无分享,去创建一个
E. Winer | V. Falanga | D. Treaba | A. Chorzalska | S. Al-Homsi | P. Dubielecka | N. Kouttab | J. Reagan | A. Olszewski | P. Marjon | C. Schorl | H. Shafqat | C. Bryke | T. C. Zhao | J. Morgan | Saad Khan | Ibrahem Salloum
[1] M. Loh,et al. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. , 2013, Blood.
[2] M. Konopleva,et al. The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem Cells , 2013, Advances in hematology.
[3] D. Campana,et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. , 2012, Blood.
[4] D. Scadden,et al. The stem cell niche: tissue physiology at a single cell level. , 2012, The Journal of clinical investigation.
[5] I. Ben-Sahra,et al. Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. , 2012, Journal of molecular cell biology.
[6] Charalampos G. Kalodimos,et al. Domain organization differences explain Bcr-Abl’s preference for CrkL over CrkII , 2012, Nature chemical biology.
[7] D. Scadden,et al. The haematopoietic stem cell niche at a glance , 2011, Journal of Cell Science.
[8] C. Eckert,et al. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse , 2011, Haematologica.
[9] A. Bennaceur-Griscelli,et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. , 2011, Blood.
[10] Susan Branford,et al. BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment , 2011, Clinical Cancer Research.
[11] K. Anderson,et al. Essential role for Abi1 in embryonic survival and WAVE2 complex integrity , 2011, Proceedings of the National Academy of Sciences.
[12] M. Konopleva,et al. Leukemia stem cells and microenvironment: biology and therapeutic targeting. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Druker,et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.
[14] Jacob R. Haling,et al. Abl-interactor-1 (Abi1) has a role in cardiovascular and placental development and is a binding partner of the α4 integrin , 2010, Proceedings of the National Academy of Sciences.
[15] P. Defilippi,et al. Integrin signalling adaptors: not only figurants in the cancer story , 2010, Nature Reviews Cancer.
[16] C. Eaves,et al. Insights into the stem cells of chronic myeloid leukemia , 2010, Leukemia.
[17] B. Mayer,et al. Abi1/Hssh3bp1 pY213 links Abl kinase signaling to p85 regulatory subunit of PI‐3 kinase in regulation of macropinocytosis in LNCaP cells , 2010, FEBS letters.
[18] D. Scadden,et al. The leukemic stem cell niche: current concepts and therapeutic opportunities. , 2009, Blood.
[19] G. Superti-Furga,et al. Charting the molecular network of the drug target Bcr-Abl , 2009, Proceedings of the National Academy of Sciences.
[20] A. Pendergast,et al. Regulation of Cell-Cell Adhesion by Abi/Diaphanous Complexes , 2009, Molecular and Cellular Biology.
[21] Yiguo Hu,et al. Beta-catenin Is Essential for Survival of Leukemia Stem Cells Insensitive to Kinase Inhibition in Mice with BCR-ABL Induced Chronic Myeloid Leukemia. , 2008 .
[22] Petra Beli,et al. WAVE and Arp2/3 jointly inhibit filopodium formation by entering into a complex with mDia2 , 2008, Nature Cell Biology.
[23] T. Holyoake,et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors , 2008, Leukemia.
[24] H. Qian,et al. Distinct roles of integrins alpha6 and alpha4 in homing of fetal liver hematopoietic stem and progenitor cells. , 2007, Blood.
[25] M. Gasparetto,et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.
[26] G. Mills,et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. , 2007, Cancer research.
[27] T. Rudel,et al. A new interaction between Abi-1 and βPIX involved in PDGF-activated actin cytoskeleton reorganisation , 2006, Cell Research.
[28] J. Melo,et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. , 2005, Cancer research.
[29] K. Rottner,et al. Abi1 regulates the activity of N-WASP and WAVE in distinct actin-based processes , 2005, Nature Cell Biology.
[30] R. Hwang,et al. Integrin α4β1–VCAM-1–mediated adhesion between endothelial and mural cells is required for blood vessel maturation , 2005 .
[31] C. Burge,et al. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.
[32] Andrea Disanza,et al. Abi1 is essential for the formation and activation of a WAVE2 signalling complex , 2004, Nature Cell Biology.
[33] A. Koleske,et al. Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation , 2004, Nature Cell Biology.
[34] H. Kuroda,et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia , 2003, Nature Medicine.
[35] G. Scita,et al. Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1 , 2003, The Journal of cell biology.
[36] B. Druker,et al. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). , 2002, Cancer research.
[37] S. McKenna,et al. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype , 2001, Leukemia.
[38] G. Scita,et al. An effector region in Eps8 is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actin–polymerizing machine , 2001, The Journal of cell biology.
[39] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[40] L. Gibson,et al. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. , 2000, Blood.
[41] M. Varella‐Garcia,et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.
[42] C. Betsholtz,et al. EPS8 and E3B1 transduce signals from Ras to Rac , 1999, Nature.
[43] D. Cortez,et al. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. , 1998, Genes & development.
[44] R. Oostendorp,et al. VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. , 1997, Leukemia & lymphoma.
[45] S. Goff,et al. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. , 1995, Genes & development.
[46] M. Labow,et al. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. , 1995, Development.
[47] R. Hynes,et al. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. , 1995, Development.
[48] A. Vara,et al. A single mRNA encodes the α150 and α80/70 forms of the α subunit of VLA4 , 1992 .
[49] T. Papayannopoulou,et al. Hematopoietic stem cell mobilization: updated conceptual renditions , 2013, Leukemia.
[50] D. Scadden,et al. The hematopoietic stem cell niche. , 2012, Frontiers in bioscience.
[51] R. Hwang,et al. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. , 2005, The Journal of clinical investigation.
[52] Paul Dent,et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. , 2002, Cancer research.
[53] A. Vara,et al. A single mRNA encodes the alpha 150 and alpha 80/70 forms of the alpha subunit of VLA4. , 1992, European journal of immunology.